- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05658471
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC) (SREC22)
Comparative Pharmacokinetics and Pharmacodynamics of Nicotine With Use of NIDA Standardized Research Electronic Cigarette (SREC) vs Usual Brand E-cigarette
Study Overview
Status
Detailed Description
OBJECTIVES:
I. To characterize nicotine delivery, systemic exposure and effects from SREC in comparison with usual to usual nicotine brand use.
II. To assess aspects of harm of SREC use compared to usual nicotine brand use.
OUTLINE:
Eligible participants will be assigned to one of two treatment conditions for the initial assessment which will take place in a hospital setting. The participant will then be assigned to the second condition within 2 weeks after the initial assessment which will also take place in a hospital setting to repeat the same procedures.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lisa Lawrence
- Phone Number: 415-608-4864
- Email: Lisa.Lawerence@ucsf.edu
Study Contact Backup
- Name: Angie Bustos
- Email: Angie.Bustos@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco - Tobacco Research Center
-
Principal Investigator:
- Neal Benowitz, MD
-
Contact:
- Angie Bustos
- Phone Number: 415-608-4864
- Email: angie.bustos@ucsf.edu
-
Contact:
- Lisa Lawrence
- Phone Number: 628-206-4204
- Email: lisa.lawrence@ucsf.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Healthy on the basis of medical history and limited physical examination-
- Heart rate < 105 beats per minute (BPM)*.
- Systolic Blood Pressure < 160 and > 90*.
- Diastolic Blood Pressure < 100 and > 50*.
- *considered out of range if both machine and manual readings are above/below these thresholds.
- Body Mass Index <= 38.0.
Current regular user of electronic cigarettes (EC)
- EC device use at least 15 or more days in the past 30 days (with e- liquid >= 3mg/ml)
- No restriction on flavor or type of e-cigarette used
- Saliva cotinine >= 50 ng/ml and/or NicAlert = 6
- Age >= 21 years old <= 70 years old
- Willingness to abstain from drug use for the duration of the study
Exclusion Criteria:
The following unstable medical conditions:
- Heart disease
- Seizures
- Cancer
- Thyroid disease (okay if controlled with medication)
- Diabetes
- Hepatitis B or C or Liver disease
- Glaucoma
- Kidney disease or urinary retention
- History of stroke
- An ulcer in the past year
- Active use of an inhaler for Asthma or chronic obstructive pulmonary disease (COPD)
Medications
- Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).
- Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers).
- Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum).
- Any stimulant medications (example: Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment.
Other/Misc. Health Conditions
- Oral thrush
- Fainting (within the last 30 days)
- Other "life threatening illnesses" as per principal investigator and/or study physician's discretion
Pregnancy
- Pregnancy (self-reported and urine pregnancy test)
- Breastfeeding (determined by self-report)
- Women of childbearing potential must be using an acceptable method of contraception
- Concurrent participation in another clinical trial.
- Inability to read and write in English
- Planning to quit smoking or vaping within the next 60 days
- A known propylene glycol/vegetable glycerin allergy
- Uncomfortable with getting blood drawn
- Recent onset or change (worsening) in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Usual Brand E-Cigarette (EC) then SREC
Participants will be admitted to hospital research ward within 32 hours of the orientation visit and begin a standardized session of product use using the usual brand of e-cigarette that participants utilize for nicotine use, and will provide expired carbon dioxide samples, pharmacokinetic (PK) blood samples, urine samples, and have cardiovascular and vital signs monitored.
Participants will also be asked to complete nicotine-related questionnaires.
Participants will then return within 2 weeks to repeat the procedures using the SREC.
|
Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.
Usual brand e-cigarettes will be provided at the hospital stay.
Other Names:
Blood, urine, and expired carbon dioxide will be obtained during the course of the study.
Other Names:
Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
Other Names:
|
Experimental: SREC then Usual Brand E-Cigarette (EC)
Participants will be admitted to hospital research ward within 32 hours of the orientation visit and begin a standardized session of product use using the SREC, and will provide expired carbon dioxide samples, pharmacokinetic (PK) blood samples, urine samples, and have cardiovascular and vital signs monitored.
Participants will also be asked to complete nicotine-related questionnaires.
Participants will then return within 2 weeks to repeat the procedures using the usual brand of e-cigarette that participants utilize for nicotine use.
|
Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.
Usual brand e-cigarettes will be provided at the hospital stay.
Other Names:
Blood, urine, and expired carbon dioxide will be obtained during the course of the study.
Other Names:
Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Peak Nicotine Concentration
Time Frame: Collected 2, 5, 7, 10, 15, 30, 45, 60, 75, 90, and 120 minutes post end vaping session
|
The investigators will compare peak nicotine concentrations between SREC vs. EC use
|
Collected 2, 5, 7, 10, 15, 30, 45, 60, 75, 90, and 120 minutes post end vaping session
|
Mean Time of Peak Nicotine Concentration
Time Frame: Collected 2, 5, 7, 10, 15, 30, 45, 60, 75, 90, and 120 minutes post end vaping session
|
Compare peak nicotine concentration between SREC vs. EC use.
|
Collected 2, 5, 7, 10, 15, 30, 45, 60, 75, 90, and 120 minutes post end vaping session
|
Area Under the plasma nicotine concentration-time Curve (AUC) at 120 minutes
Time Frame: Collected 2, 5, 7, 10, 15, 30, 45, 60, 75, 90, and 120 minutes post end vaping session
|
Compare peak nicotine concentration between SREC vs. EC
|
Collected 2, 5, 7, 10, 15, 30, 45, 60, 75, 90, and 120 minutes post end vaping session
|
Mean overall systemic nicotine exposure
Time Frame: during the 3 hr of ad libitum use
|
Descriptive statistics will be used to examine systemic nicotine exposure from use of SREC and compare to EC
|
during the 3 hr of ad libitum use
|
Mean inter-puff interval
Time Frame: during the 3 hr of ad libitum use
|
The patterns of SREC puffing and EC use will be examined looking at the average and variability (SD) of inter-puff interval during the 3 hr of ad libitum use.
|
during the 3 hr of ad libitum use
|
Change in Mean score on the Modified Cigarette Evaluation Questionnaire (mCEQ)
Time Frame: Up to 1 month
|
The mCEQ use three multi-item domains (subscales) and two single items: "Smoking Satisfaction", "Psychological Reward", "Aversion", "Enjoyment of Respiratory Tract Sensations" and "Craving Reduction".
Scores for each subscale are calculated as the average of its individual item responses of The items are rated on a seven-point scale ranging from 1 (not at all) to 7 (extremely).
Higher scores indicate greater intensity of each smoking effect with, for example, greater satisfaction or psychological reward after smoking.
Scores will be compared between SREC and EC use.
|
Up to 1 month
|
Change in Mean score on the Minnesota Tobacco Withdrawal Scale-Revised (MTWS-R)
Time Frame: Up to 1 month
|
The MTWS-R features two separate measures for examining the severity of nicotine withdrawal symptoms in a participant: a self-report scale and an observer scale.
The observer scale asks the scale-taker to rate the severity of four symptoms in someone the they know who is experiencing nicotine withdrawal: "angry/irritable/frustrated," "anxious/tense," "depressed," and "restless/impatient."
The self-report version asks for rankings of the severity of those same four symptoms, plus eleven others that cannot be observed by outsiders (including such things as "desire or craving to smoke," "insomnia, sleep problems, awakening at night," or "dizziness).
Both scales use a Likert-type scale for the severity ratings, ranging from 0 ("not at all") to 4 ("severe").
These scores are tallied to calculate an a total withdrawal discomfort score and will be compared between SREC and EC use
|
Up to 1 month
|
Change in Mean score on the Questionnaire on Smoking Urges (QSU-Brief)
Time Frame: Up to 1 month
|
The QSU-Brief consists of 10 statements about the respondent's feelings and thoughts about the participants desire to smoke cigarettes as the participant is completing the questionnaire (i.e., right now).
Each response is scored a number ranging from 1 (strongly disagree) to 7 (strongly agree) and total scores are calculated by summing the item scores to compare craving between SREC and EC use
|
Up to 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean acrolein levels within participants
Time Frame: Up to 1 month
|
Urine excretion of mercapturic acid metabolites of volatile organic compounds (VOCs), with a particular focus on acrolein will be measured and compared between SREC and EC use
|
Up to 1 month
|
Mean propylene oxide levels within participants
Time Frame: Up to 1 month
|
Urine excretion of mercapturic acid metabolites of VOCs, with a particular focus on propylene oxide will be measured and compared between SREC and EC use
|
Up to 1 month
|
Median benzene levels within participants
Time Frame: Up to 1 month
|
Urine excretion of mercapturic acid metabolites of VOCs, with a particular focus on benzene will be measured and compared between SREC and EC use
|
Up to 1 month
|
Mean heart rate within participants
Time Frame: Up to 1 month
|
The cardiovascular effects of e-cigarette use as measured by heart rate will be compared between SREC and EC use
|
Up to 1 month
|
Mean blood pressure (both systolic and diastolic) within participants
Time Frame: Up to 1 month
|
The cardiovascular effects of e-cigarette use as measured by blood pressure will be compared between SREC and EC use
|
Up to 1 month
|
Mean plasma epinephrine within participants
Time Frame: Up to 1 month
|
The cardiovascular effects of e-cigarette use as measured by plasma epinephrine will be compared between SREC and EC use
|
Up to 1 month
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Neal Benowitz, MD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SREC22
- 5U01DA045519-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nicotine Dependence
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)WithdrawnCardiovascular Risk Factor | Nicotine Dependence | Nicotine Dependence, Cigarettes | Nicotine Withdrawal | Tobacco ToxicityUnited States
-
University of VermontNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence, CigarettesUnited States
-
Freedom Laser, Inc.NST Consultants, Inc.Completed
-
University of VermontNational Institute of General Medical Sciences (NIGMS)CompletedNicotine Dependence, CigarettesUnited States
-
Milton S. Hershey Medical CenterCompleted
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruitingNicotine Dependence, CigarettesCzechia, Norway
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruiting
-
Duke UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence, CigarettesUnited States
-
Milton S. Hershey Medical CenterTerminatedNicotine Dependence, CigarettesUnited States
Clinical Trials on Standardized Research E-Cigarette (SREC)
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)WithdrawnCardiovascular Risk Factor | Nicotine Dependence | Nicotine Dependence, Cigarettes | Nicotine Withdrawal | Tobacco ToxicityUnited States
-
Brown UniversityRecruiting
-
Massachusetts General HospitalNot yet recruiting
-
University of Southern CaliforniaUniversity of CaliforniaActive, not recruitingCigarette SmokingUnited States
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingSerum Biomarkers | Vascular ReactivityUnited States
-
Masonic Cancer Center, University of MinnesotaNational Institute on Drug Abuse (NIDA)RecruitingSmoking, CigaretteUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaFondazione Salvatore MaugeriCompleted
-
University of OklahomaCompletedSmoking CessationUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Roswell Park Cancer InstituteCompleted
-
University of California, Los AngelesTobacco Related Disease Research ProgramCompleted